Raymond James Trust N.A. Trims Stake in Baxter International Inc. (NYSE:BAX)

Raymond James Trust N.A. lessened its stake in Baxter International Inc. (NYSE:BAXGet Rating) by 3.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 38,284 shares of the medical instruments supplier’s stock after selling 1,218 shares during the period. Raymond James Trust N.A.’s holdings in Baxter International were worth $2,459,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in BAX. Banco de Sabadell S.A increased its position in Baxter International by 16.7% during the 4th quarter. Banco de Sabadell S.A now owns 19,302 shares of the medical instruments supplier’s stock worth $1,658,000 after purchasing an additional 2,759 shares during the period. Altavista Wealth Management Inc. increased its position in Baxter International by 26.3% during the 4th quarter. Altavista Wealth Management Inc. now owns 4,804 shares of the medical instruments supplier’s stock worth $412,000 after purchasing an additional 1,000 shares during the period. Alpha Paradigm Partners LLC acquired a new position in Baxter International during the 4th quarter worth approximately $700,000. Laurel Wealth Advisors Inc. acquired a new position in Baxter International during the 4th quarter worth approximately $484,000. Finally, Wellington Shields Capital Management LLC increased its position in Baxter International by 61.3% during the 4th quarter. Wellington Shields Capital Management LLC now owns 13,150 shares of the medical instruments supplier’s stock worth $1,129,000 after purchasing an additional 4,999 shares during the period. Institutional investors and hedge funds own 84.69% of the company’s stock.

Baxter International Trading Down 0.2 %

Shares of Baxter International stock opened at $55.37 on Friday. Baxter International Inc. has a fifty-two week low of $54.45 and a fifty-two week high of $89.70. The firm has a market cap of $27.88 billion, a PE ratio of 27.69, a P/E/G ratio of 2.01 and a beta of 0.60. The business’s fifty day moving average is $59.90 and its two-hundred day moving average is $68.42. The company has a quick ratio of 1.33, a current ratio of 2.01 and a debt-to-equity ratio of 1.83.

Baxter International (NYSE:BAXGet Rating) last issued its quarterly earnings results on Thursday, July 28th. The medical instruments supplier reported $0.87 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.87. Baxter International had a return on equity of 21.75% and a net margin of 7.12%. The company had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.88 billion. During the same quarter in the prior year, the company posted $0.80 EPS. The business’s revenue for the quarter was up 20.9% compared to the same quarter last year. Analysts anticipate that Baxter International Inc. will post 3.63 earnings per share for the current year.

Baxter International Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, October 3rd. Investors of record on Friday, September 2nd will be given a $0.29 dividend. This represents a $1.16 annualized dividend and a dividend yield of 2.09%. The ex-dividend date is Thursday, September 1st. Baxter International’s dividend payout ratio (DPR) is currently 58.00%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Wells Fargo & Company cut Baxter International from an “overweight” rating to an “equal weight” rating and set a $71.00 price target on the stock. in a report on Friday, June 24th. Stifel Nicolaus lowered their price target on Baxter International from $85.00 to $75.00 in a report on Monday, July 18th. Morgan Stanley lowered their price target on Baxter International from $86.00 to $72.00 and set an “overweight” rating on the stock in a report on Friday, July 29th. The Goldman Sachs Group restated a “sell” rating and issued a $60.00 price target (down previously from $70.00) on shares of Baxter International in a report on Wednesday, August 3rd. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on Baxter International from $99.00 to $69.00 in a report on Friday, July 29th. One analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.69.

Baxter International Profile

(Get Rating)

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit.

Featured Stories

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc. (NYSE:BAXGet Rating).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.